-
1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Assays
2026-09-10
PP 3 provides a practical negative-control arm for experiments testing whether PP 2 effects truly depend on Src kinase activity. Its value is greatest in matched biochemical, cellular, and vascular workflows where DMSO exposure, concentration, timing, and orthogonal readouts are controlled rigorously.
-
SCH772984 HCl: Practical ERK1/2 Inhibition Workflows
2026-09-09
SCH772984 HCl is a nanomolar ERK1/2 inhibitor for dissecting MAPK-driven proliferation, resistance, and spatial translation. This guide connects cancer-focused workflows with cardiomyocyte assays inspired by recent findings on nuclear ERK and 4EBP1 phosphorylation, while emphasizing controls, timing, and troubleshooting.
-
2,2,2-Trichloroethanol: Reliable Protein Analysis
2026-09-09
Learn how 2,2,2-Trichloroethanol, SKU C6823, can support standardized protein electrophoresis and molecular biology workflows without being misrepresented as a direct cell-viability reagent. This scenario-based guide covers compatibility, handling, vendor selection, data interpretation, and limitations using product documentation and relevant translational research.
-
ICAA Targets RIP3 in Cardiac Hypertrophy
2026-09-09
A 2026 Cellular Signalling study identifies receptor-interacting protein 3 (RIP3) as a previously underappreciated regulator of angiotensin II- and pressure overload-induced cardiac hypertrophy. Its data position the RIP3/CaMKII axis, rather than the canonical RIP3/MLKL necroptosis pathway alone, as a mechanistic target of isochlorogenic acid A (ICAA).
-
Trametinib and Tumor Evolution in CRC Models
2026-09-08
Trametinib (GSK1120212) is more than a potent MEK1/2 inhibitor: it can serve as an evolution-aware oncology research tool for connecting ERK suppression with heterogeneous colorectal cancer responses. This article integrates its mechanism with patient-derived xenograft and multi-omics insights from metastatic CRC research.
-
AG-126 (Tyrphostin AG-126): ERK Pathway Guide
2026-09-07
AG-126, also called Tyrphostin AG-126, is a research inhibitor of ERK1 and ERK2 phosphorylation with reported in vitro activity at 25–50 μM. Product evidence also describes cytokine release inhibition and activity in a rat pneumococcal cell wall inflammation model, but it does not establish clinical efficacy or a role in autism-related repetitive behavior.
-
HOXC8, Caspase-1, and Pyroptosis in NSCLC
2026-09-07
The reference study shows that HOXC8 promotes non-small cell lung carcinoma survival by repressing CASP1 transcription through HDAC1/2 recruitment, thereby limiting pyroptotic cell death. Its findings connect transcriptional control, inflammatory caspase abundance, and tumorigenesis, while suggesting experimental strategies for separating pyroptosis from other forms of cell death.
-
TH287: A Radiosensitization Strategy in CRPC
2026-09-05
TH287 reframes MTH1 inhibition as a way to convert oxidative nucleotide stress into a controllable radiosensitization strategy. This article examines the mechanism, evidence from CRPC cell models, treatment-sequence implications, compound handling, translational limitations, and the next experiments needed to move beyond a conventional product-page view.
-
Deferoxamine mesylate: Reliable Assay Workflows
2026-09-04
Learn how Deferoxamine mesylate (SKU B6068) can help researchers control labile iron, oxidative stress, and hypoxia-linked biology in viability, proliferation, cytotoxicity, and wound-healing assays. This scenario-based guide connects formulation data with ferroptosis interpretation, practical preparation, and evidence-aware product selection.
-
Colorectal Metastasis and Therapeutic Heterogeneity
2026-09-04
Cho et al. show that colorectal cancer metastasis is accompanied by coordinated changes in mutations, gene expression, and DNA methylation, rather than by a simple linear accumulation of genomic events. Matched patient-derived xenografts demonstrate that metastatic evolution can produce site-specific drug responses through newly acquired subclonal alterations or activation of bypass signaling.
-
DDX3 RNA Helicase Crystallization: Study Insights
2026-09-03
Rodamilans and Montoya established a reproducible crystallization and preliminary X-ray diffraction workflow for the human DDX3 helicase domain, addressing a major gap in structural information for this disease-relevant RNA helicase. The study shows that spermine tetrahydrochloride formed part of a condition yielding crystals that diffracted to 2.2 Å, creating a platform for future mechanistic and inhibitor studies.
-
DAPI Nuclear Stain Solution Protocol
2026-09-03
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution K2402 provides a ready-to-use fluorescent DNA binding dye for nuclear visualization and endpoint assessment of membrane integrity. It is best suited to fixed or membrane-compromised samples analyzed by fluorescence microscopy or flow cytometry, rather than routine imaging of intact live cells.
-
Carrier-Free Triterpene Prodrug for OSCC Therapy
2026-09-02
This ACS Applied Materials & Interfaces study developed a carrier-free prodrug from glycyrrhetinic acid and ginsenoside Rh2 for targeted oral squamous cell carcinoma treatment. Its thioketal linker, glucose-associated uptake, and glycyrrhetinic-acid-driven ROS feedback enabled self-boosted release and synergistic tumor-cell apoptosis while avoiding a conventional nanocarrier.
-
Trametinib Workflow for MEK-ERK Research
2026-09-02
Build a controlled Trametinib (GSK1120212) workflow that connects MEK-ERK signaling to phospho-ERK, cell-cycle, apoptosis, and TERT chromatin readouts. The guide emphasizes dose design, hESC-compatible assay choices, B-RAF comparison, and troubleshooting for reproducible oncology research.
-
Torin2 Workflows for mTOR Pathway Research
2026-09-01
Torin2 combines subnanomolar mTOR inhibition with a practical workflow for viability, migration, apoptosis, and combination studies. This guide shows how to use it in medullary thyroid carcinoma models while separating mTOR-dependent effects from broader transcriptional stress and assay artifacts.